ASMB
ASSEMBLY BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$19.87
−0.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$20.37
From 52W high−48.39%
Volume269004.00
Market cap$404.57M
P/E (TTM)36.1x
P/S (TTM)5.4x
Div yield—
Key dataNov 4, 2026
Open
$20.37
From 52W high
−48.39%
Volume
269004.00
Market cap
$404.57M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1272.9x
P/E (TTM)
36.1x
RSI (14)
36.0
MomentumView details →
1D Return
−0.25%
YTD Return
−41.78%
SummaryUpdated Jun 1, 2026
Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotechnology company founded in 2005 and headquartered in South San Francisco, California. Originally incorporated as Ventrus Biosciences, the company changed its name to Assembly Biosciences in June 2014. The company went public in December 2010 and focuses exclusively on developing therapeutic treatments for hepatitis B virus (HBV) infection, a serious liver disease that affects hundreds of millions of people worldwide.
Similar companies
Latest newsMore news →
ASSEMBLY BIOSCIENCES, INC. dosed the first two participants in a Phase 2 study of oral ABI-6250 for chronic hepatitis delta virus.6d agoAssembly Biosciences announced it will present positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at AASLD The Liver Meeting 2026.31d agoAssembly Biosciences exercised its U.S. profit-share option with Gilead Sciences for its HSV helicase-primase inhibitor program, agreeing to share 40% of U.S. development costs and profits.57d ago